longer apply. Applicants thus respectfully request the Restriction be reviewed and either withdrawn or modified in light of the following amendment and reasons.

AMENDMENT

In the Claims:

Kindly amend the claims as follows:

Please cancel claims 1, 2 and 4-29.

Please replace claim 3 with the following

3. (amended) A polyamine analogue or derivative represented by the formula

$$R\text{-}CO\text{-}NH\text{-}(CH_2)_3\text{-}NH\text{-}(CH_2)_4\text{-}NH\text{-}(CH_2)_3\text{-}NH_2$$

wherein R is a head group selected from the group consisting of a straight or branched $C_{1\text{-}10}$ aliphatic, alicyclic, single or multi-ring aromatic, single or multi-ring aryl substituted aliphatic, aliphatic-substituted single or multi-ring aromatic, a single or multi-ring heterocyclic, a single or multi-ring heterocyclic-substituted aliphatic and an aliphatic-substituted aromatic or

wherein R-CO- is a D or L amino acid or ornithine,

wherein said analogue or derivative is not compound 1022, 1085, 1111, 1163 1166, 1202, or 1260.

Please insert new claims 30-45.

30. An analogue or derivative according to claim 3 wherein R is a straight aliphatic.

31. An analogue or derivative according to claim 3 wherein R is branched aliphatic.

32. An analogue or derivative according to claim 3 wherein R is alicyclic or aromatic.

33. An analogue or derivative according to claim 3 wherein R is a D or L amino acid or ornithine.

34. A composition comprising a polyamine analogue or derivative according to any one of claims 3 or 30-33 and a pharmaceutically acceptable excipient.

35. A composition comprising a polyamine analogue or derivative according to claim 3, a pharmaceutically acceptable excipient, and an inhibitor of polyamine synthesis.

36. A composition according to claim 35 herein said inhibitor of polyamine synthesis is difluoromethylornithine (DFMO).

37. A method for treating a disease or a condition in a subject associated with undesired cell proliferation and/or which is treatable by inhibition of polyamine transport, comprising administering to said subject a polyamine analogue or derivative according to claim 3.

38. A method according to claim 37 wherein said undesired cell proliferation is associated with proliferation of cells of the immune system, cell of the vascular neontima, tumor cells or with undesired angiogenesis.

39. A method according to claim 37 wherein said disease or condition is cancer or post-angioplasty injury.

40. A method according to claim 37 further comprising administration of an inhibitor of polyamine synthesis.

41. A method according to claim 40 wherein said inhibitor of polyamine synthesis is difluoromethylornithine (DFMO).

42. A composition according to claim 35 or 36 in solid form.

43. A composition according to claim 35 or 36 in liquid form.

44. A method according to any one of claims 37-41 wherein said administering is performed orally, parenterally, topically, transdermally, intravaginally, intranasally, intrabronchially, intracranially, intraocularly, intraaurally, or rectally, or by injection.

45. A method according to claim 44 wherein said administering by injection is intravenous, subcutaneous, intramuscular, intracranial, or intraperitoneal.